USFDA25 Aug 2026, 04:03 pm
Cipla's Pithampur facility receives 7 USFDA observations
AI Summary
Cipla Ltd announced that its manufacturing facility in Pithampur, India, underwent a follow-up current Good Manufacturing Practices (cGMP) inspection by the USFDA from August 17-25, 2026. Following the inspection, the company received seven observations in Form 483. Cipla has stated its commitment to working closely with the USFDA to address these observations comprehensively within the stipulated timeframe. This follows previous intimations regarding the facility's regulatory status.
Key Highlights
- USFDA conducted a follow-up cGMP inspection at Pithampur facility.
- Seven inspectional observations (Form 483) were received.
- Company committed to addressing observations within stipulated time.
- This is a follow-up to previous regulatory intimations.
Price Impact
More from CIPLA